What is the current stock price of Jasper Therapeutics, Inc. (JSPR)?

As of the latest market data, Jasper Therapeutics, Inc. (JSPR) is trading at $0.80. The stock has seen a loss of -2.59% today.

Does Jasper Therapeutics, Inc. (JSPR) pay a dividend?

Based on current data, Jasper Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Jasper Therapeutics, Inc.?

The current market capitalization of Jasper Therapeutics, Inc. (JSPR) is approximately unavailable.

JSPR

Jasper Therapeutics, Inc.·Healthcare

0.80

2.586%(−0.02)

Market Closed

1.00

24.143%(+0.19)

After Hours

Last Updated: — ET

52W L: $0.6252W H: $7.19

JSPR NEWS

globenewswire.com

Mar 30

Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year ended December 31, 2025 and provided a corporate update.

247wallst.com

Mar 23

Here Are Monday’s Top Wall Street Analyst Research Calls: APA Corporation, Cheniere Energy, Crown Castle, Hut 8, MongoDB, Red Rock Resorts, Super Micro Computer, Terawulf, and More

Pre-Market Stock Futures: Futures are trading higher after President Trump signalled that talks with Iran are progressing positively, as we get ready to start another trading week, with the same issues that have dragged the stock market down for four consecutive weeks still in place. While we have had a virtual March Madness in stocks,... Here Are Monday's Top Wall Street Analyst Research Calls: APA Corporation, Cheniere Energy, Crown Castle, Hut 8, MongoDB, Red Rock Resorts, Super Micro Computer, Terawulf, and More.

globenewswire.com

Feb 24

Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the 46th Annual TD Cowen Healthcare Conference, taking place March 2-4, 2026 in Boston, MA.

Company Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2020-01-10

Beta

3.20

Websitejaspertherapeutics.com↗